Unexplained Recurrent Pregnancy Loss: New Therapeutic Perspectives

Status

Active, not recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06867900

Enrollment

Registered

2025-03-10

Start date

2021-01-01

Completion date

2025-07-06

Last updated

2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Miscarriage, Recurrent

Keywords

Recurrent pregnancy loss

Brief summary

Evaluation of gut permeability and endometrial inflammasome NLRP3 in women with unexplaid recurrent pregnancy loss before-after administration of Bifidobacteriumlongum ES1.

Interventions

DIETARY_SUPPLEMENTBifidobacterium Longum ES1

Oral administration of Bifidobacterium Longum ES1 for three months.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Idiopathic recurrent pregnancy loss * Genetic predisposition to celiac disease

Exclusion criteria

Design outcomes

Primary

Measure	Time frame	Description
Assessment of Endometrial inflammation in RPL women	3 months	Analysis of the inflammasome NALP3 expression and activation in serum and endometrial fluid in women with unexplained recurrent pregnancy loss compared to women with uncomplicated pregnancy history.
Assessment of Gut permeability status in RPL women	3 months	Analysis of zonulin expression and activation in serum and endometrial fluid in women with unexplained recurrent pregnancy loss compared to women with uncomplicated pregnancy history.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026